PART I Overview We are a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. We have built a business focused on developing and commercializing innovative therapeutics that we believe serve as a foundation for future growth, including by contributing net product revenue to support the development and advancement of our robust pipeline of mid-stage programs targeting rare kidney diseases and early-stage programs targeting kidney disease...
Q2 FY2026 — expected 2026-08-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001517022-26-000020 | EDGAR | 155K words |
| 2025-03-13 | 2024-12-31 | 0001628280-25-012470 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0001628280-24-011270 | EDGAR | — |
| 2023-03-10 | 2022-12-31 | 0001628280-23-007539 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001628280-22-004522 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001628280-21-003283 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001564590-20-010491 | EDGAR | — |
| 2019-03-26 | 2018-12-31 | 0001564590-19-009340 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001564590-18-005286 | EDGAR | — |
| 2017-03-06 | 2016-12-31 | 0001564590-17-003466 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001517022-26-000051 | EDGAR | — |
| 2025-11-10 | 2025-09-30 | 0001517022-25-000046 | EDGAR | 91K words |
| 2025-08-07 | 2025-06-30 | 0001628280-25-038600 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001628280-25-023460 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001628280-24-045979 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001628280-24-035879 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001628280-24-021945 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001628280-23-037557 | EDGAR | — |
| 2023-08-28 | 2023-06-30 | 0001628280-23-030698 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001628280-23-016258 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001628280-22-028242 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-021096 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-05 | 0001517022-26-000050 | EDGAR | — |
| 2026-04-01 | 0001517022-26-000024 | EDGAR | 1K words |
| 2026-02-26 | 0001517022-26-000019 | EDGAR | — |
| 2026-01-30 | 0001517022-26-000008 | EDGAR | — |
| 2026-01-12 | 0001517022-26-000003 | EDGAR | — |
| 2025-12-01 | 0001517022-25-000051 | EDGAR | — |
| 2025-11-17 | 0001517022-25-000048 | EDGAR | — |
| 2025-11-10 | 0001517022-25-000045 | EDGAR | — |
| 2025-10-28 | 0001517022-25-000040 | EDGAR | — |
| 2025-08-07 | 0001517022-25-000034 | EDGAR | — |
253 total filings indexed. 221 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001517022 |
| Ticker | AKBA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.akebia.com |
| Listed | 2014-03-20 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/AKBA (~200 tokens, structured JSON with cryptographic provenance)